Gyre Therapeutics Inc (GYRE) — Institutional Holders Breakdown (Q2 2026)

GYRE ranks #5603 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

63 institutions disclose a position in GYRE, but none treat it as a major bet — even HSG Holding Ltd, its most concentrated holder, allocates just 2.1% of its own portfolio to it.

GYRE is down 5% today, but institutions show net buying of $36.1M this quarter — a divergence between today's price move and the underlying institutional flow.

GYRE reported a net loss of $28.2M over the trailing twelve months.

• Not yet profitable — net loss of $28.2M over the trailing twelve months
• Revenue grew 13.5% year over year
• Net income declined year over year, from $6.2M to -$28.2M
• Generated $1.0M in positive operating cash flow
• Current ratio of 5.60x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.22x equity — within a conventional range